SCHEMBL2658022

SCHEMBL2658022

Cc1ccc2c(O)ccnc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.54
ADRA1D P25100 4/20 0.54
ADRA1A P35348 4/20 0.54
ADRA1B P35368 4/20 0.54
ALDH1A1 P00352 3/20 0.46
CHEK1 O14757 1/20 0.44
PARP1 P09874 1/20 0.44
PIM1 P11309 1/20 0.44
RPS6KA3 P51812 1/20 0.44
TLR8 Q9NR97 3/20 0.44
TRPA1 O75762 1/20 0.41
TP53 P04637 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
UHRF1 Q96T88 1/20 0.40
CCR1 P32246 1/20 0.40
CCR5 P51681 1/20 0.40
CCR8 P51685 1/20 0.40
SLC22A12 Q96S37 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539379 0.84 HTR1A (0.54) HTR1AADRA1DADRA1AADRA1BALDH1A1
Ethoxycarbonyl Group SCHEMBL27796056 0.82 HTR1A (0.43) HTR1AADRA1DADRA1AADRA1BALDH1A1
SCHEMBL29509132 0.79 TLR8 (0.54) ALDH1A1TLR8TDP1KDM4EMEN1
SCHEMBL28164080 0.79 TLR8 (0.54) ALDH1A1TLR8TDP1KDM4EMEN1
SCHEMBL873159 0.79 HTR1A (0.58) HTR1AADRA1DADRA1AADRA1BALDH1A1
SCHEMBL15960727 0.78 TLR8 (0.45) HTR1AADRA1DADRA1AADRA1BALDH1A1
SCHEMBL30772330 0.76 NR4A2 (0.61) ALDH1A1TLR8TDP1CCR1KDM4E
SCHEMBL29933815 0.76 FERMT2 (0.49) TLR8SLC22A12KDM4ETGFBR1
SCHEMBL409748 0.76 NR4A2 (0.61) ALDH1A1TLR8TDP1CCR1KDM4E
SCHEMBL1490718 0.76 ALK (0.50) ALDH1A1TLR8SLC22A12KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563103-A modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto 艾尼纳制药公司 2019-04-02 CN claimed
EP-4055014-B1 PYRROLIDINE AND PIPERIDINE COMPOUNDS YUHAN CORP (KR) 2025-04-30 EP disclosed
CN-114867719-B Pyrrolidine and piperidine compounds 柳韩洋行 2024-06-25 CN disclosed
CN-117986220-A Method for preparing substituted chromanone derivative 杭州杜易科技有限公司 2024-05-07 CN disclosed
CN-114222734-B Method for preparing substituted chromanone derivative 杭州杜易科技有限公司 2023-12-08 CN disclosed
US-11655235-B2 Pyrrolidine and piperidine compounds YUHAN CORPORATION (KR) 2023-05-23 US disclosed
CN-111039942-B Nitrogen-containing heterocyclic compound, and preparation method, pharmaceutical composition and application thereof 上海长森药业有限公司 2023-04-14 CN disclosed
US-11560386-B2 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2023-01-24 US disclosed
EP-3464292-B1 MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2022-09-21 EP disclosed
EP-4055014-A1 PYRROLIDINE AND PIPERIDINE COMPOUNDS Yuhan Corporation (KR) 2022-09-14 EP disclosed
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2002-06-13 US disclosed
US-6323200-B1 THE COMPOUNDS ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT THE T-HELPER-TYPE 2 IMMUNE RESPONSE. 3M INNOVATIVE PROPERTIES COMPANY 2001-11-27 US disclosed
CN-1320126-A Oxazolo, thiazolo and selenazolo [4, 5-C ] quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES CO (US) 2001-10-31 CN disclosed
EP-1100802-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M Innovative Properties Company (US) 2001-05-23 EP disclosed
US-6110929-A IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-08-29 US disclosed
WO-2000006577-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-02-10 WO disclosed
US-4508902-A OXIDATION OF 1,2,3,4-TETRAHYDROQUINOLINE-4-ONES RHONE-POULENC SANTE (FR) 1985-04-02 US disclosed
US-4447435-A HYPOTENSIVE AGENTS THE BOOTS COMPANY PLC (GB) 1984-05-08 US disclosed
US-4442109-A 3-Methylthiomethyl-and 3-methylsulfinylmethyl-4-quinolinones useful for treating hypertension THE BOOTS COMPANY LIMITED (GB) 1984-04-10 US disclosed
US-4412076-A Preparation of 4-hydroxyquinolines RHONE-POULENC SANTE (FR) 1983-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 HTR1A 3697/4885ADRA1D 4361/4885ADRA1A 4268/4885
US-11655235-B2 Pyrrolidine and piperidine compounds FAP, APC, VHL HTR1A 4160/4885ADRA1D 3563/4885ADRA1A 4172/4885
US-11560386-B2 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto ADRB3, ADRB1, ADRB2 HTR1A 715/4885ADRA1D 9/4885ADRA1A 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.